SINGAPORE, May 14, 2014 /CNW/ - Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I), a developer of leading-edge photonics technologies for medical,
industrial and scientific markets, today announced that the United
States District Court of Ohio issued its patent claim construction
ruling, or Markman Order, yesterday regarding the ongoing patent
infringement action against defendants Saint-Gobain Corporation and
Philips. The joint claims construction hearing, also known as the
Markman hearing, was held before the Court on July 1 and 2, 2013.
In a Markman Order, the presiding district court sets out the meaning of
certain disputed patent claim language present in the patent. The
interpretation of the language in the patent is then applied during the
action in the determination of infringement and validity of the patent
claim. The Markman Order can play a significant role in the progress
and outcome of patent infringement litigation.
In the Order issued yesterday, the Court adopted interpretations that
Zecotek believes are favorable on the key terms in the litigation
The lawsuit, filed on February 23, 2012, alleges that Saint-Gobain's
LYSO crystals infringe Zecotek's patent, and that Philips infringes by
using those crystals in the PET scanners it sells
"We are very pleased with the Court's interpretations of key terms
presented at the Markman Hearing," said Dr. A.F. Zerrouk, Chairman,
President, and CEO of Zecotek Photonics Inc. "We remain confident in
our position and look forward to a just resolution of this action."
U.S. Patent No. 7,132,060, granted to Zecotek on November 6, 2006, is
part of Zecotek's portfolio of over 50 patented and patent pending
novel photonic technologies. The patent covers the substances and
chemical formulations used to grow lutetium fine silicate (LFS)
scintillation crystals which are characterized by their combined high
light yield and ultra-fast decay times and are typically used in
medical scanning devices.
Zecotek Photonics Inc (TSX-V: ZMS; Frankfurt: W1I) is a photonics
technology company developing high-performance scintillation crystals,
photo detectors, positron emission tomography scanning technologies, 3D
auto-stereoscopic displays, and lasers for applications in medical,
high-tech and industrial sectors. Founded in 2004, Zecotek operates
three divisions: Imaging Systems, Laser Systems and 3D Display Systems
with labs located in Canada, Korea, Russia, Singapore and U.S.A. The
management team is focused on building shareholder value by
commercializing over 50 patented and patent pending novel photonic
technologies directly and through strategic alliances and joint
ventures with leading industry partners including Hamamatsu Photonics
(Japan), the European Organization for Nuclear Research (Switzerland),
Beijing Opto-Electronics Technology Co. Ltd. (China), NuCare Medical
Systems (South Korea), the University of Washington (United States),
and National NanoFab Center (South Korea). For more information visit www.zecotek.com, follow @zecotek on Twitter and "like" us in Facebook at www.facebook.com/zecotek.
This press release may contain forward-looking statements that are based
on management's expectations, estimates, projections and assumptions.
These statements are not guarantees of future performance and involve
certain risks and uncertainties, which are difficult to predict.
Therefore, actual future results and trends may differ materially from
what may have been stated.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of the content of
this news release. If you would like to receive news from Zecotek in
the future please visit the corporate website at www.zecotek.com.
Image with caption: "Zecotek - Leading the way in photonics! (CNW Group/Zecotek Photonics Inc.)". Image available at: http://photos.newswire.ca/images/download/20140514_C8231_PHOTO_EN_40266.jpg
SOURCE: Zecotek Photonics Inc.
For further information:
Zecotek Photonics Inc.
T: (604) 783-8291